查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363983

2023-2030年全球呼吸道合胞病毒诊断市场

Global Respiratory Syncytial Virus Diagnostic Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

预计全球呼吸道合胞病毒诊断市场在预测期内（2023-2030年）复合年增长率将达到6.5%。呼吸系统疾病发病率上升、新生儿数量增加、体外诊断需求不断增长以及对护理设施的需求不断增长是推动市场扩张的几个主要原因。根据美国国立卫生研究院 (NIH) 2022 年 11 月发布的报告，90.0% 的儿童在生命的头两年内感染 RSV，成人和年龄较大的儿童经常再次感染 RSV。大多数 RSV 患者会出现上呼吸道疾病，但相当一部分人也会出现下呼吸道疾病，主要是细支气管炎。例如，2023年7月，美国批准阿斯特捷利康和赛诺菲生产的Beyfortus（nirsevimab）用于治疗新生儿、婴儿和24个月以下儿童的呼吸道合胞病毒（RSV）下呼吸道疾病（LRTD）在第一个RSV 季节期间或刚开始时出生。

细分市场前景

全球呼吸道合胞病毒诊断市场按产品、方法和最终用户细分。根据产品，市场细分为试剂盒和检测以及仪器。根据方法，市场细分为快速抗原检测、分子诊断、直接萤光抗体方法、免疫测定等。此外，根据最终用户，市场分为医院、诊所和实验室。在这些产品中，由于针对呼吸道合胞病毒的基于萤光焦点的高通量微中和测试的开发不断增加，预计试剂盒和检测细分市场将占据相当大的市场份额。

预计分子诊断细分市场将在全球呼吸道合胞病毒诊断市场中占据相当大的份额

其中，分子诊断细分领域预计将在全球呼吸道合胞病毒诊断市场中占据相当大的份额。细分市场的成长归因于慢性病对全球人口的影响日益增加；预计呼吸道疾病将会频繁增加。预计这也将增加市场对检测 RSV 等传染病的分子诊断的需求。例如，2021 年 3 月，GENETWORx Labs 宣布了一项诊断测试，该测试将所有三种不同呼吸道病毒（Flu AB、COVID-19 和 RSV）的早期识别结合到一个针对患者的测试样本中。 TCA/GENETWORx Flu AB/COVID 组合检测是一种分子诊断 PCR 检测，可识别甲型和乙型流感病毒，并将其与 RSV 和引起 COVID-19 的 SARS-CoV-2 病毒区分开来。它还可以检测两种类型的流感病毒：甲型流感病毒和乙型流感病毒。

区域展望

全球呼吸道合胞病毒诊断市场根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（英国、义大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国） 、日本、韩国和亚洲其他地区）以及世界其他地区（中东和非洲以及拉丁美洲）。其中，由于该地区呼吸道合胞病毒感染负担增加，预计亚太地区将在全球市场中占据显着份额。投资、技术开发、产品批准和推出、政府努力以及主要市场参与者采取的其他主要策略的增加。主要参与者包括Jacobson Pharma、Ascletis Pharma Inc.、Nuance Pharma、Sino Bioogical Inc.、VedaLab等。

预计北美在全球呼吸道合胞病毒诊断市场中将以显着的复合年增长率成长

在所有地区中，北美地区预计在预测期内将以相当大的复合年增长率成长。区域成长归因于生物和奈米技术 (PCR) 等现代方法的发展，有助于开发 RSV 检测技术，包括蛋白质印迹、酶联免疫吸附试验 (ELISA)、直接免疫萤光和即时聚合酶链反应。此外，许多国家的政府组织为研发计划提供资金，以创造新的治疗方法。临床疫苗研究数量的增加、体外诊断需求的增加、小儿肺炎盛行率的增加以及分子​​诊断使用的增加是预计推动市场的其他因素。这些都是推动该地区市场扩张的具体因素。

与其他程序相比，快速抗原测试的有效性、增加产品推出以及重要的政府和市场参与者活动都预计将促进区域成长。由于婴儿和幼儿RSV感染的发生率较高。根据美国国家过敏和传染病研究所（NIAID）2022年7月发布的报告，据估计，RSV感染每年导緻美国65岁以上成年人1.4万人死亡。据认为，RSV 每年影响全球 6,400 万人，并导致全球 16 万人死亡。分子方法具有极高的特异性、内部检查和快速的周转时间，因此前景广阔。与患者群体中的免疫测定相比，分子诊断在该地区的应用越来越广泛。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • Becton, Dickinson and Company
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • BioMerieux SA
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • F. Hoffmann-La Roche Ltd.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按产品分類的全球呼吸道合胞病毒诊断市场
    • 试剂盒和检测
    • 仪器
  • 按方法分類的全球呼吸道合胞病毒诊断市场
    • 快速抗原检测测试
    • 分子诊断
    • 直接萤光抗体法
    • 免疫测定
    • 其他（流式细胞仪）
  • 最终用户的全球呼吸道合胞病毒诊断市场
    • 医院
    • 诊所
    • 实验室

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Abbott Laboratories
  • Beckman Coulter Inc.
  • BioCartis, Hologic, Inc
  • Bio-Rad Laboratories, Inc.
  • CorisBioConcept
  • Danaher
  • DiaSorin Molecular LLC.
  • Fast Track Diagnostics Luxembourg S.a R.L.
  • Luminex Corp.
  • Merck KGaA
  • NorgenBiotek Corp.
  • Ortho Clinical Diagnostics
  • Quest Diagnostics
  • QuidelOrtho Corporation
  • Siemens Healthcare Diagnostics Inc.
  • Virax Biolabs
Product Code: OMR2027690

Title: Global Respiratory Syncytial Virus Diagnostic Market Size, Share & Trends Analysis Report by Product (Kits and Assays, Instruments), by Method (Rapid Antigen Detection Tests, Molecular Diagnostics, Direct Fluorescent Antibody Method, Immunoassays and Others), and by End-Users (Hospitals, Clinics, and Laboratories),Forecast Period (2023-2030).

The global respiratory syncytial virus diagnostic market is anticipated to grow at a significant CAGR of 6.5% during the forecast period (2023-2030). Rising incidence rates of respiratory illnesses, increasing newborn populations, an expanding need for in-vitro diagnostics, and rising demand for point-of-care facilities are a few of the main reasons propelling market expansion. According to a National Institute of Health (NIH) report published in November 2022, 90.0% of children get RSV within the first two years of life, and adults and older children frequently get it again. The majority of RSV patients will experience upper respiratory sickness, but a sizeable proportion will also experience lower respiratory illness, primarily bronchiolitis. For instance, in July 2023, US approved Beyfortus (nirsevimab), Manufactured by AstraZeneca and Sanofi, for the treatment of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns, infants, and children up to 24 months old who were born during or just beginning their first RSV season.

Segmental Outlook

The global respiratory syncytial virus diagnostic market is segmented on the product, method, and end-users. Based on the product, the market is sub-segmented into kits and assays, and instruments. Based on the method, the market is sub-segmented into rapid antigen detection tests, molecular diagnostics, direct fluorescent antibody methods, immunoassays, and others. Further, on the basis of end-users, the market is sub-segmented into hospitals, clinics, and laboratories. Among the products, the kits and assay sub-segment is anticipated to hold a considerable share of the market owing to the increase in the development of a fluorescent focus-based, high-throughput microneutralization test for the respiratory syncytial virus.

The Molecular Diagnostics Sub-Segment is Anticipated to Hold a Considerable Share of the Global Respiratory Syncytial Virus Diagnostic Market

Among the methods, the molecular diagnostics sub-segment is expected to hold a considerable share of the global respiratory syncytical virus diagnosis market. The segmental growth is attributed to the increasing impact of chronic diseases on the global population; respiratory illnesses are projected to grow frequently. This is also anticipated to increase demand for molecular diagnostics in the market for testing infectious diseases like RSV. For instance, in March 2021, GENETWORx Labs announced a diagnostic test that combines the early identification of all three distinct respiratory viruses-Flu A-B, COVID-19, and RSV-in a single test sample for patients. The TCA/GENETWORx Flu A-B/COVID Combo Test is a molecular diagnostic PCR test that identifies influenza A and B viruses and distinguishes them from RSV and SARS-CoV-2, the virus that causes COVID-19. It also detects two types of influenza viruses, influenza A and B.

Regional Outlook

The global respiratory syncytial virus diagnostic market is further segmented based on geography, including North America (the US and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the increased burden of respiratory syncytial virus infections in the region. Rise in investments, technical development, product approvals and launches, government efforts, and other major strategies taken by the key market participants. The key players include Jacobson Pharma, Ascletis Pharma Inc., Nuance Pharma, Sino BioogicalInc.,VedaLab and others.

The North America is Anticipated to Grow at a Significant CAGR in the Global Respiratory Syncytial Virus Diagnostic Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to development of modern methods like bio- and nanotechnology (PCR) are helping to develop RSV detection technologies including the western blot, enzyme-linked immunosorbent test (ELISA), direct immunofluorescence, and real-time polymerase chain reaction. In addition, government organizations from many nations provide funding for R&D initiatives to create new treatments. A rise in the number of clinical vaccine studies, an increase in the need for in-vitro diagnostics, an increase in the prevalence of pediatric pneumonia, and a rise in the use of molecular diagnostics are additional factors anticipated to propel the market. These are the specific factors driving market expansion in the region.

Rapid antigen test effectiveness compared to other procedures, increasing product introductions, and significant government and market participant activities are all anticipated to enhance regional growth. Owing to the higher occurrence of RSV infections in babies and young children. According to National Institute of Allergy and Infectious Disease (NIAID), report published in July 2022, According to estimates, RSV infection cause 14,000 death in US adults over 65 each year. RSV is thought to affect 64 million people globally each year, and cause death of 160,000 people globally. With their great specificity, internal checks, and rapid turnaround times, molecular approaches hold promise. Compared to immunoassays in the patient group, molecular diagnostics are becoming more widely used in the region.

Market Players Outlook

The major companies serving the respiratory syncytial virus includes diagnostic market Abbott Laboratories, Bio-Rad Laboratories, Inc., DiaSorin Molecular LLC., NorgenBiotek Corp., Siemens Healthcare Diagnostics Inc. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in February 2021, BARDA and Luminex Corp. collaborate on a single, rapid diagnostic test to distinguish coronavirus from influenza and RSV infections. With the help of this grant from BARDA, Luminex Corporation will be able to complete the development work necessary to submit an application to the FDA for Emergency Use Authorization (EUA) of the ARIES Flu A/B & RSV+SARS-CoV-2 Assay and to get 510(k) clearance for this combo test.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global respiratory syncytial virus diagnostic market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Becton, Dickinson and Company
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. BioMerieux SA
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. F. Hoffmann-La Roche Ltd.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Respiratory Syncytial Virus Diagnostic Market by Product
    • 4.1.1. Kits and Assays
    • 4.1.2. Instruments
  • 4.2. Global Respiratory Syncytial Virus Diagnostic Market by Method
    • 4.2.1. Rapid Antigen Detection Tests
    • 4.2.2. Molecular Diagnostics
    • 4.2.3. Direct Fluorescent Antibody Method
    • 4.2.4. Immunoassays
    • 4.2.5. Others (Flow Cytometry)
  • 4.3. Global Respiratory Syncytial Virus Diagnostic Market by End-Users
    • 4.3.1. Hospitals
    • 4.3.2. Clinics
    • 4.3.3. Laboratories

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Abbott Laboratories
  • 6.2. Beckman Coulter Inc.
  • 6.3. BioCartis, Hologic, Inc
  • 6.4. Bio-Rad Laboratories, Inc.
  • 6.5. CorisBioConcept
  • 6.6. Danaher
  • 6.7. DiaSorin Molecular LLC.
  • 6.8. Fast Track Diagnostics Luxembourg S.a R.L.
  • 6.9. Luminex Corp.
  • 6.10. Merck KGaA
  • 6.11. NorgenBiotek Corp.
  • 6.12. Ortho Clinical Diagnostics
  • 6.13. Quest Diagnostics
  • 6.14. QuidelOrtho Corporation
  • 6.15. Siemens Healthcare Diagnostics Inc.
  • 6.16. Virax Biolabs

LIST OF TABLES

  • 1. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 2. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC KITS AND ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC INSTRUMRNT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
  • 5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA RAPID ANTIGEN DETECTION TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA DIRECT FLUORESCENT ANTIBODY METHOD MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA IMMUNOASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL OTHERS RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)
  • 11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. NORTH AMERICAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)
  • 19. EUROPEAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 20. EUROPEAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 21. EUROPEAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
  • 22. EUROPEAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)
  • 23. ASIA- PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 24. ASIA- PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 25. ASIA- PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
  • 26. ASIA- PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)
  • 27. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PROUCT, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022 VS 2030 (%)
  • 2. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC KITS AND ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC INSTRUMRNT MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022 VS 2030 (%)
  • 5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA RAPID ANTIGEN DETECTION TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA DIRECT FLUORESCENT ANTIBODY METHOD MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA IMMUNOASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL OTHERS RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022 VS 2030 (%)
  • 11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. US RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. CANADA RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. UK RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. FRANCE RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. GERMANY RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. ITALY RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. SPAIN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. REST OF EUROPE RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. INDIA RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. CHINA RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. JAPAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. SOUTH KOREA RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)